Cellectis (CLLS) Other financing activities (2022 - 2023)
Cellectis (CLLS) posted Other financing activities of $1.3 million for Q2 2023, up 151.98% on a QoQ basis from $506000.0 in Q1 2023, and up 417.16% year-over-year from $246536.8 in Q2 2022.
Cellectis (CLLS) has 2 years of Other financing activities data on file, last reported at $1.3 million in Q2 2023.
- In Q2 2023, Other financing activities rose 417.16% year-over-year to $1.3 million; the TTM figure through Dec 2023 stood at $1.8 million (down 79.41% YoY), while the FY2023 annual figure was $1.8 million, down 79.41% from the prior year.
- Other financing activities rose to $1.3 million in Q2 2023, from $506000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $10.6 million in Q1 2022 and bottomed at -$1.3 million in Q3 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 1.28 Mn |
| Jun 30, 2023 | 1.28 Mn |
| Mar 31, 2023 | 506,000.00 |
| Mar 31, 2023 | 506,000.00 |
| Dec 31, 2022 | -254,000.00 |
| Dec 31, 2022 | -254,000.00 |
| Sep 30, 2022 | -1.30 Mn |
| Sep 30, 2022 | -1.30 Mn |
| Jun 30, 2022 | -402,000.00 |
| Jun 30, 2022 | -402,000.00 |
| Mar 31, 2022 | 10.61 Mn |
| Mar 31, 2022 | 10.61 Mn |